NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
24 trialsNCT05132582 2026-03-16
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07102381 2026-03-12
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT03006172 2026-03-11
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT05325632 2026-03-02
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07053085 2026-02-27
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07421141 2026-02-27
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Active not recruiting
NCT05113251 2026-02-23
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT06686394 2026-02-13
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02624973 2026-02-12
PETREMAC
Haukeland University Hospital
Phase 2 Active not recruiting
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07386938 2026-02-04
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
R-Pharm
Phase 3 Active not recruiting
NCT05150691 2026-01-28
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05296798 2026-01-16
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03199885 2025-12-30
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT07294508 2025-12-29
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting